Ads
related to: bispecific monoclonal antibody- Engineering Services
An Antibody Engineering Solution
For Every Research Need.
- Contact Us
Looking For A Custom Antibody?
Contact Us With Your Project Needs.
- Sequencing Services
Secure A Precisely Defined &
Reproducible Source Of Antibodies.
- Recombinant Antibodies
An Ever-Expanding Protein Catalog
For Research & Diagnostics.
- Engineering Services
scbt.com has been visited by 10K+ users in the past month
Search results
Results from the WOW.Com Content Network
A bispecific monoclonal antibody (BsMAb, BsAb) is an artificial protein that can simultaneously bind to two different types of antigen or two different epitopes on the same antigen. [1] Naturally occurring antibodies typically only target one antigen. BsAbs can be manufactured in several structural formats.
BsAb: bispecific monoclonal antibody: 3funct: trifunctional antibody; BiTE: bi-specific T-cell engager; This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate
Like other bispecific antibodies, and unlike ordinary monoclonal antibodies, BiTEs form a link between T cells and tumor cells. This causes T cells to exert cytotoxic activity on tumor cells by producing proteins like perforin and granzymes, independently of the presence of MHC I or co-stimulatory molecules.
Bispecific monoclonal antibodies can also be engineered, by increasing the therapeutic targets of one monoclonal antibody to two epitopes. It is possible to produce monoclonal antibodies that specifically bind to almost any suitable substance; they can then serve to detect or purify it.
Single-chain variable fragments lack the constant Fc region found in complete antibody molecules, and, thus, the common binding sites (e.g., protein G) cannot be used to purify antibodies. These fragments can often be purified or immobilized using protein L , since protein L interacts with the variable region of kappa light chains.
The bispecific antibodies have arrived in the clinic. In 2009, the bispecific antibody catumaxomab was approved in the European Union [40] [41] and was later withdrawn for commercial reasons. [42] Others include amivantamab, blinatumomab, teclistamab, and emicizumab. [43]
Ads
related to: bispecific monoclonal antibodyscbt.com has been visited by 10K+ users in the past month